Citations 1
A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial.
Konecny, Gottfried E. , Jänicke, F., Beckmann, Matthias W. , Feisel, Gabriele, Pölcher, Martin , Rody, Achim , Ray-Coquard, Isabelle Laure, Provencher, Diane , Ben‐Baruch, Noa, Cottu, Paul , Chen, Hsiao‐Wang, Dering, Judy, Jacod, Sylvie, Houé, Vincent, Slamon, Dennis J. , Haluska, Paul , Sehouli, Jalid , Roman, Lynda D. , Karlan, Beth Y. , Wang, Chen
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 5529-5529
